Ethicon Launches New Echelon+ Stapler With GST Reloads To Increase Staple Line Security And Reduce Complications In Surgery

April 1, 2021

Ethicon recently announced the global launch of the ECHELON+ Stapler with GST Reloads, a new powered surgical stapler designed to increase staple line security and reduce complications through more uniform tissue compression and better staple formation, even in challenging situations.

The ECHELON+ Stapler is the latest addition to the company’s market-leading ECHELON Powered Stapler portfolio.  The portfolio has been associated with improved clinical and economic outcomes including fewer bleeding complications, reduced hospital costs, and improved efficiency across, procedures, patient populations, and countries in large-scale retrospective studies.

Several innovative design features distinguish the new device from previous staplers including a reengineered ECHELON+ Anvil, that with Gripping Surface Technology (GST) Reloads, is designed for more uniform compression to better capture and form staples, as well as a new motor with Dynamic Firing, which optimizes firing speed in thick tissue to enhance compression and improve audible feedback. In recent benchtop testing, the ECHELON+ Stapler outperformed Medtronic’s Signia and EndoGIA Staplers with Tri-Staple Reloads providing better staple formation and reducing leaks at the staple line.

“The ECHELON+ Stapler is a meaningful innovation that addresses a key concern of bariatric surgeons, improving staple line security to help reduce complications,” said Joseph Northup, MD, Medical Director, Premier Weight Loss Solutions.

Despite recent advances in surgical stapling technology, perioperative complications persist across specialties.  Complications are driven primarily by postoperative anastomotic leaks and bleeding-related complications which may occur in up to 12% of colorectal resections and in 2% to 10% of lobectomies, respectively.

“The launch of the ECHELON+ Stapler with GST Reloads is another milestone in our continuing commitment to evidence-based innovation that can enhance the surgeon’s experience, improve patient outcomes and deliver meaningful clinical and economic value. Our goal is to always elevate the standard of surgical care,” said Tom O’Brien, Worldwide Endomechanical President, Ethicon.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”